Published Online: Friday, June 1, 2007
Brand name prescription drugs with annual sales of >$140 billion are in line to lose patent protection between now and 2016, according to a new analysis that bodes well for the generic pharmaceutical industry?s prospects during the coming decade. The analysis by researchers at Data-monitor predicts that the peak of the patent expirations will occur during 2011 and 2012, when heavily prescribed branded products such as clopi-dogrel bisulfate (Plavix), atorvas-tatin calcium (Lipitor), fluticasone  propionate and salmeterol inhalation powder (Advair), and queti-apine fumarate (Seroquel) will face generic competition for the first time.

Latest Articles
Acute respiratory infections such as the common cold are often accompanied by cough and congestion caused by mucus hypersecretion.
Poor medication adherence is responsible for unnecessary illness, hospitalizations, disability, and premature death, particularly among patients with chronic diseases.
Police and a CVS pharmacy are on the lookout for a man who stole several boxes of diabetic test strips.
The FDA has approved Merck’s supplemental new drug application for single-dose fosaprepitant dimeglumine for injection.
Latest Issues